bioMérieux, a world leader in the field of in vitro diagnostics, announces that BioFire Diagnostics, its molecular biology affiliate, has submitted to the Food and Drug Administration for 510(k) clearance of the BIOFIRE® Blood Culture Identification 2 (BCID2) Panel. The BIOFIRE® BCID2 Panel includes several additional pathogens, an expanded list of antimicrobial resistance genes, and many revised targets compared to the existing BIOFIRE® BCID Panel.
Canada
MNA Rizqy and Minister Fitzgibbon honor the employees of bioMérieux Canada Inc. with the National Assembly Medal for their exceptional contribution during the COVID-19 pandemic
27 June, 2022The bioMérieux Canada team remained true to its commitment towards public health by ensuring the installation of the BIOFIRE® systems in record time. The team traveled across Canada despite the sanitary restrictions to ensure adequate user training and was able to demonstrate agility and innovation...
bioMérieux submits enhanced BIOFIRE® BCID2 Panel for FDA clearance
14 January, 2020
bioMérieux – 2019 Financial Results
14 January, 2020
bioMérieux – Third-Quarter 2019 Business Review
22 October, 2019
bioMérieux – First-Half 2019 Results
04 September, 2019
bioMérieux – Second-Quarter 2016 Business Review
18 July, 2016
bioMérieux, a world leader in the field of in vitro diagnostics, today released its quarterly business review for the six months ended June 30, 2016.
bioMérieux enlarges its pathogen identification capability on VITEK® MS
06 July, 2016
With a database of more than 15,000 strains VITEK® MS improves clinical decision-making for infectious diseases.
bioMerieux Receives FDA Clearance for Expanded Use of VIDAS® B•R•A•H•M•S PCT™ Test for Managing Sepsis Patients with Elevated Risk of Mortality
01 July, 2016
Tracking PCT – a biomarker for bacterial infections – over time provides strong indication of likely mortality, enabling physicians to personalize care for high-risk patients.
bioMérieux acquires Hyglos
01 June, 2016
bioMérieux acquires Hyglos and expands its offering to the detection of endotoxins in pharmaceutical products.
bioMérieux and the Lyon Civil Hospitals strengthen their collaboration
31 May, 2016
bioMérieux and the Lyon Civil Hospitals strengthen their collaboration and expand their partnership to include Claude Bernard University Lyon 1 Two joint research laboratories focused on a common goal: advancing medical research for the benefit of patients.